EX-5.1 2 ex_540897.htm EXHIBIT 5.1 ex_540897.htm

Exhibit 5.1

 

d01.jpg

Dentons US LLP

1221 Avenue of the
Americas, New York
NY 10020-1089 United States

dentons.com

 

July [ ], 2023

 

 

SAB Biotherapeutics, Inc.

2100 East 54th Street North

Sioux Falls, South Dakota 57104

 

Re:

SAB Biotherapeutics, Inc. Post-Effective Amendment to Registration Statement on Form S-3

 

Ladies and Gentlemen:

 

In our capacity as counsel to SAB Biotherapeutics, Inc. a Delaware corporation (the “Company”), we have been asked to render this opinion in connection with a Post-Effective Amendment (the “Post-Effective Amendment”) to the Registration Statement on Form S-3, originally filed by the Company with the Securities and Exchange Commission (the “Commission”) on May 1, 2023 (the “Registration Statement,” and the prospectus which forms a part of the Registration Statement, as amended by the Post-Effective Amendment, the “Prospectus”) under the Securities Act of 1933, as amended (the “Act”). The Post-Effective Amendment, filed on July [ ], 2023, covers the resale of up to an aggregate of 2,216,894 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), including (i) 1,916,894 shares (the “Shares”) of Common Stock and (ii) 300,000 shares (the “Warrant Shares”) of Common Stock issuable upon exercise of warrants (the “Warrants”).

 

We are delivering this opinion to you at your request in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Act.

 

In connection with rendering this opinion, we have examined and are familiar with the Company’s (i) certificate of incorporation and bylaws, each as amended and restated; (ii) the Registration Statement, as amended by the Post-Effective Amendment, including the Prospectus; (iii) the form of Warrant, (iv) corporate proceedings of the Company relating to the issuance of the securities described herein; and (v) and such other instruments and documents as we have deemed relevant under the circumstances.

 

In making the aforesaid examinations, we have assumed the genuineness of all signatures and the conformity to original documents of all copies furnished to us as original or photostatic copies. We have also assumed that the corporate records furnished to us by the Company include all corporate proceedings taken by the Company to date. We have assumed without investigation that there has been no relevant change or development between the dates as of which the information cited in the preceding sentence was given and the date of this letter. As to certain factual matters, we have relied upon a certificate of officers of the Company and have not sought to independently verify such matters.

 

Based upon the foregoing, and in reliance thereon, and subject to the qualifications, limitations and exceptions stated herein, we are of the opinion, having due regard for such legal considerations as we deem relevant, that (i) the Shares are validly issued, fully paid and non-assessable, and (ii) the Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and non-assessable.

 

Our opinion herein is expressed solely with respect to the Delaware General Corporation Law of the State of Delaware. Our opinion is based on these laws as in effect on the date hereof and as of the effective date of the Post-Effective Amendment, and we assume no obligation to revise or supplement this opinion after the effective date of the Post-Effective Amendment should the law be changed by legislative action, judicial decision or otherwise. Where our opinions expressed herein refer to events to occur at a future date, we have assumed that there will have been no changes in the relevant law or facts between the date hereof and such future date. Our opinions expressed herein are limited to the matters expressly stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Not in limitation of the foregoing, we are not rendering any opinion as to the compliance with any other federal or state law, rule or regulation relating to securities, or to the sale or issuance thereof.

 

 

 

We hereby consent to the use of our opinion as Exhibit 5.1 to the Post-Effective Amendment and to the reference to this firm and this opinion under the heading “Legal Matters” in the Prospectus comprising a part of the Registration Statement, as amended to the Post-Effective Amendment, and any amendment thereto. In giving such consent, we do not hereby admit that we come within the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Commission thereunder.

 

 

Very truly yours,

 

/s/ Dentons US LLP

Dentons US LLP

 

Zaanouni Law Firm & Associates ► LuatViet ► Fernanda Lopes & Associados ► Guevara & Gutierrez ► Paz Horowitz Abogados ► Sirote ► Adepetun Caxton-Martins Agbor & Segun ► Davis Brown ► East African Law Chambers ► For more information on the firms that have come together to form Dentons, go to dentons.com/legacyfirms